<DOC>
	<DOCNO>NCT00455364</DOCNO>
	<brief_summary>The purpose study compare safety efficacy Voriconazole Itraconazole follow lung transplantation .</brief_summary>
	<brief_title>Voriconazole Prophylactic Therapy Lung Transplant Recipients</brief_title>
	<detailed_description>All participant receive itraconazole inpatient post transplant stay . As outpatient , ten subject randomize receive itraconazole 200mg orally daily 6 month ten patient receive voriconazole 200mg orally twice daily 6 month . All subject follow clinic per standard transplant treatment</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Bilaterallung singlelung transplant recipient age 18 65 year old . Patients must able give informed consent prior transplantation Lung transplant patient unable give inform consent . Prior adverse reaction drug itraconazole voriconazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Fungal infection prophylaxis</keyword>
	<keyword>Lung transplant</keyword>
	<keyword>Fungal infection post lung transplant</keyword>
</DOC>